Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Measurable residual disease in newly diagnosed multiple myeloma: Experience from a large cohort from an academic medical center

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAndrés ArroyoACAjai ChariSAShagun Arora

Discussion

Loading...

Member takes

Overview

Cohort study finds measurable residual disease status predicts improved progression-free survival and overall survival in multiple myeloma patients after treatment.

Key Points

  • Evaluate the association of measurable residual disease status with patient outcomes in multiple myeloma.
  • Reviewed clinical records of patients with multiple myeloma at UCSF.
  • Assessed measurable residual disease using bone marrow samples and the clonoSEQ® assay.
  • Defined high-risk cytogenetics as t(4;14), t(14;16) or del(17p).
  • Analyzed outcomes based on MRD status post-autologous stem cell transplantation.
  • 186 patients (42.3%) achieved MRD- status, correlating with improved progression-free survival (PFS) and overall survival (OS).
  • Median follow-up was 42.5 months for ASCT patients with MRD- status.
  • MRD- status post-ASCT at 1 and 2 years was predictive of better PFS; earlier assessments were not prognostic.

Cite This Study

Arroyo et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0c5https://doi.org/10.1182/blood-2025-2234
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival2025
  2. 2What remains matters: Real-world impact of measurable residual disease testing in multiple myeloma2025
  3. 3Cytogenetics-based clinical trajectories of patients with MRD negativity post autologous stem cell transplant for multiple myeloma2025
  4. 4Detection of minimal residual disease after induction chemotherapy and autologous HSCT and its clinical significance in multiple myeloma2025
  5. 5Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy2025 · 6 citations